Abstract Body

Direct-Acting Antivirals (DAAs) eradicate HCV and reduce liver fibrosis by containing inflammation. Virologic response correlates with the restoration of NK and CD8, however, little is known on the effects of DAAs on gd, Th17 and Treg which all play a role in liver fibrogenesis. Further, while B-cell activation has been linked to extrahepatic manifestations of HCV, literature is lacking on the role of these cells in liver damage.

We enrolled 97 virally-infected (VI) subjects (15 HIV cART-suppressed; 35 HCV naive to HCV therapy; 47 HIV/HCV cART-suppressed and naive to HCV therapy) and 10 age-matched healthy controls (HC). All HCV-infected individuals underwent DAA therapy. At baseline (T0) and 12 weeks after End of Treatment (SVR12) we measured: (i) γδ frequency (CD3+Pan γδ+), activation (CD69/CD38), (ii) Th17-like (CD4+CD161+CCR6+); (iii) Treg (CD4+CD25+CD127-); (iv) B cell frequency (CD19+), activation (CD86/CD38); v) γ-globulin levels.vi) Fibrosis stage was determined by transient elastography (Fibroscan) Statistical analysis as appropriate

At T0, VI presented lower Th17 and higher Treg versus HC (Fig1A). DAA led to a further contraction of Th17 and no changes in Treg frequency (Fig.1B). While total γδ were comparable in VI and HC both prior to and following treatment (Fig.1B), activated γδ subset decreased upon DAA (Fig.1C). Compared to HC, VI also featured higher B-cell frequencies and activation which both decreased during DAA (Fig1C). Accordingly, γ-globulin concentrations also diminished in HCV mono and co-infection following DAA and correlated with B-cell activation (Fig1D). In VI, a low vδ2/Th17 ratio, known to predict liver damage, increased from baseline to SVR12, yet remained lower than HC (HIV/HCV vs HC: p=.04; HCV vs HC: p=.03) and negatively correlated with liver stiffness (Fig.1E)  and serum ALT and AST (Fig.1F) Further, also γ-globulin levels were positively linked to liver fibrosis indexes following DAAs (r=0.6, p<.0001). No differences in B and T cell phenotypes were registered (Fig1A).

Effective DAA in both HCV- mono and HIV/HCV co-infected subjects resulted in decreased B- and γδ cell activation, with recovery of vδ2/Th17 ratio. These changes are linked to the reduction of hepatic necrosis and stiffness, suggesting that DAA-mediated lightening of the pro-inflammatory liver insult may limit organ damage.